Safe Use of Antibiotics with Dofetilide

Introduction to Dofetilide and Antibiotic Interactions

• The American College of Cardiology recommends avoiding the use of certain antibiotics with dofetilide due to the risk of QT prolongation and torsades de pointes, including trimethoprim-containing medications, macrolides like clarithromycin and erythromycin, and certain azole antifungals 1

Contraindicated Antibiotics

• The American Heart Association suggests that the following medications are contraindicated with dofetilide due to significant risk of QT prolongation and torsades de pointes:

  Medication	Reason for Contraindication
  Verapamil	QT interval prolongation
  Trimethoprim-containing medications	QT interval prolongation
  Hydrochlorothiazide	QT interval prolongation
  Cimetidine	QT interval prolongation
  Dolutegravir	QT interval prolongation
  Itraconazole	QT interval prolongation
  Ketoconazole	QT interval prolongation
  Megestrol	QT interval prolongation
  Prochlorperazine	QT interval prolongation
  Trimethoprim/sulfamethoxazole	QT interval prolongation

  Patient Risk Factors

• Patients with female gender, advanced age, hypokalemia or hypomagnesemia, bradycardia, congestive heart failure, renal dysfunction, baseline QT prolongation, or concomitant use of other QT-prolonging medications require extra caution when combining any antibiotic with dofetilide 4, 5
• Patients with pre-existing QT prolongation, history of torsades de pointes, concomitant use of other QT-prolonging medications, electrolyte abnormalities, advanced age, female gender, structural heart disease, heart failure, bradycardia, or renal or hepatic dysfunction are at higher risk of clinically significant QT prolongation with prochlorperazine 6

Monitoring and Precautions

• The American College of Cardiology recommends obtaining baseline ECG before starting the antibiotic, monitoring ECG 2-4 hours after administration of the first few doses of antibiotic, checking electrolytes (especially potassium and magnesium) and correcting if abnormal, discontinuing if QT interval exceeds 500 ms or increases by >60 ms from baseline, and considering hospitalization for high-risk patients starting both medications simultaneously 4
• Baseline ECG and follow-up ECG 2-4 hours after each dose during initiation of dofetilide are recommended, with discontinuation if QT interval exceeds 500 ms, as stated by the American College of Cardiology 3, 1
• Regular monitoring of potassium and magnesium levels is necessary, with correction of electrolyte abnormalities before starting dofetilide, as recommended by the American Heart Association and American College of Cardiology 3, 1
• Electrolytes should be monitored closely, especially potassium levels, when switching from thiazide to loop diuretics, with moderate evidence supporting this recommendation, as recommended by the American Heart Association 2

Safe Use of Specific Antibiotics

• Azithromycin has less QT-prolonging potential than other macrolides, but still carries some risk, and should be used with caution, including using the lowest effective dose, limiting treatment duration, monitoring ECG closely, and maintaining normal electrolyte levels 7, 8
• Levofloxacin is preferred over other fluoroquinolones when possible due to its lower QT-prolonging potential 7, 8

Preferred Antibiotics and Alternative Medications

• Insulin, GLP-1 receptor agonists, SGLT2 inhibitors, DPP-4 inhibitors, thiazolidinediones, and sulfonylureas can be used with dofetilide with caution regarding hypoglycemia risk, as stated by the American Diabetes Association and American Association of Clinical Endocrinologists 9, 10
• Metformin requires dose adjustment based on renal function when used with dofetilide, as recommended by the American Diabetes Association 9
• Loop diuretics are recommended instead of thiazides as an alternative diuretic option, with strong evidence supporting their safety and efficacy, as recommended by the European Society of Cardiology 11
• Potassium-sparing effects can be achieved with spironolactone or eplerenone instead of triamterene, based on moderate-quality evidence, as suggested by the European Society of Cardiology 11
• Patients with preserved renal function may consider sotalol as an alternative antiarrhythmic option, with moderate evidence supporting its use, as recommended by the American Heart Association 2
• Patients who cannot take other agents may consider amiodarone as a third-line option for rhythm control, based on low-to-moderate quality evidence, as suggested by the American Heart Association 2